Comprehensive analysis of KRT18 as a novel prognostic biomarker and potential target in lung adenocarcinoma.

IF 3.5 4区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Clinical and Experimental Medicine Pub Date : 2025-09-01 DOI:10.1007/s10238-025-01855-0

Jiajia Xiao, Zhenpeng Zhu, Fengxu Yan, Zhicong Yang, Dandan Xu, Fan Zhang, Xinsheng Wang

{"title":"Comprehensive analysis of KRT18 as a novel prognostic biomarker and potential target in lung adenocarcinoma.","authors":"Jiajia Xiao, Zhenpeng Zhu, Fengxu Yan, Zhicong Yang, Dandan Xu, Fan Zhang, Xinsheng Wang","doi":"10.1007/s10238-025-01855-0","DOIUrl":null,"url":null,"abstract":"Background: The expression characteristics of Keratin 18 (KRT18) in lung adenocarcinoma (LUAD) remain incompletely elucidated. This study aims to investigate the expression pattern of KRT18 in LUAD and its prognostic significance.Methods: We analyzed the expression status of KRT18 in LUAD and its association with prognosis. Utilizing the UALCAN and STRING databases, we systematically evaluated the clinical phenotypic parameters of KRT18 and its protein-protein interaction network. Through enrichment analysis, we clarified its biological functions and associated signaling pathways, and simultaneously deciphered the association patterns between the tumor immune infiltration landscape and immune checkpoint molecules.Results: High expression of KRT18 was associated with poor prognosis in LUAD patients and was closely correlated with tumor stage and pathological stage. Functional enrichment analysis revealed that KRT18 was significantly enriched in epithelial cell differentiation and intermediate filament pathways. Immune infiltration analysis showed that the expression of KRT18 was associated with tumor immune cell infiltration and immune checkpoints. Immunohistochemistry further confirmed the high expression of KRT18 in LUAD tissues.Conclusion: Therefore, KRT18 may serve as a biomarker for the prognosis and diagnosis of LUAD and also represents a potential target for immunotherapy.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"312"},"PeriodicalIF":3.5000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12401774/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10238-025-01855-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The expression characteristics of Keratin 18 (KRT18) in lung adenocarcinoma (LUAD) remain incompletely elucidated. This study aims to investigate the expression pattern of KRT18 in LUAD and its prognostic significance.

Methods: We analyzed the expression status of KRT18 in LUAD and its association with prognosis. Utilizing the UALCAN and STRING databases, we systematically evaluated the clinical phenotypic parameters of KRT18 and its protein-protein interaction network. Through enrichment analysis, we clarified its biological functions and associated signaling pathways, and simultaneously deciphered the association patterns between the tumor immune infiltration landscape and immune checkpoint molecules.

Results: High expression of KRT18 was associated with poor prognosis in LUAD patients and was closely correlated with tumor stage and pathological stage. Functional enrichment analysis revealed that KRT18 was significantly enriched in epithelial cell differentiation and intermediate filament pathways. Immune infiltration analysis showed that the expression of KRT18 was associated with tumor immune cell infiltration and immune checkpoints. Immunohistochemistry further confirmed the high expression of KRT18 in LUAD tissues.

Conclusion: Therefore, KRT18 may serve as a biomarker for the prognosis and diagnosis of LUAD and also represents a potential target for immunotherapy.

查看原文本刊更多论文

KRT18作为肺腺癌新的预后生物标志物和潜在靶点的综合分析。

背景：角蛋白18 （Keratin 18, KRT18）在肺腺癌（LUAD）中的表达特征尚不完全清楚。本研究旨在探讨KRT18在LUAD中的表达模式及其预后意义。方法：分析KRT18在LUAD中的表达状况及其与预后的关系。利用UALCAN和STRING数据库，我们系统地评估了KRT18的临床表型参数及其蛋白-蛋白相互作用网络。通过富集分析，我们明确了其生物学功能和相关信号通路，同时破译了肿瘤免疫浸润景观与免疫检查点分子之间的关联模式。结果：KRT18高表达与LUAD患者预后不良相关，且与肿瘤分期、病理分期密切相关。功能富集分析显示KRT18在上皮细胞分化和中间丝通路中显著富集。免疫浸润分析显示KRT18的表达与肿瘤免疫细胞浸润和免疫检查点有关。免疫组化进一步证实KRT18在LUAD组织中的高表达。结论：因此，KRT18可能作为LUAD预后和诊断的生物标志物，也可能是免疫治疗的潜在靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Medicine 医学-医学：研究与实验

CiteScore

4.80

自引率

2.20%

发文量

159

审稿时长

2.5 months

期刊介绍： Clinical and Experimental Medicine (CEM) is a multidisciplinary journal that aims to be a forum of scientific excellence and information exchange in relation to the basic and clinical features of the following fields: hematology, onco-hematology, oncology, virology, immunology, and rheumatology. The journal publishes reviews and editorials, experimental and preclinical studies, translational research, prospectively designed clinical trials, and epidemiological studies. Papers containing new clinical or experimental data that are likely to contribute to changes in clinical practice or the way in which a disease is thought about will be given priority due to their immediate importance. Case reports will be accepted on an exceptional basis only, and their submission is discouraged. The major criteria for publication are clarity, scientific soundness, and advances in knowledge. In compliance with the overwhelmingly prevailing request by the international scientific community, and with respect for eco-compatibility issues, CEM is now published exclusively online.